BK Polyomavirus In Solid Organ Transplantation
Publication Date: April 1, 2019
Last Updated: March 14, 2022
RECOMMENDATIONS FOR BKPYV IN KIDNEY TRANSPLANTATION
Donor testing prior to kidney transplantation for genetic mark ers, BKPyV viruria, virus genotyping, or VLP/Vp1.specific.specific antibody levels is not recommended at the present time. (Low, Strong)
317067
Recipient testing prior to kidney transplantation for genetic markers, BKPyV VLP/Vp1‐specific antibody levels, or BKPyV (subtype)‐neutralizing antibody levels, or BKPyV‐specific T‐cell quantity or function is not recommended at the present time. (Low, Strong)
317067
Kidney transplant recipients should be screened for BKPyV DNAemia by QNAT to identify patients to be considered for preemptive treatment for PyVAN. (Moderate, Strong)
317067
Screening for BKPyV‐DNAemia by QNAT should be performed monthly until month 9, then every 3 months until 2 years posttransplant. (Moderate, Strong)
317067
Kidney transplant recipients should be tested for BKPyVDNAemia by QNAT when undergoing renal allograft biopsy for surveillance (Low, Strong)
317067
- or for cause/indication
317067
to inform histopathology studies.
Clinical virology laboratories providing screening and monitoring BKPyV‐DNAemia by QNAT in kidney transplant recipients should participate in proficiency testing by external quality assurance programs to provide information about assay performance. (Moderate, Strong)
317067
BKPyV-DNAemia should be confirmed within 3 weeks to be sus tained as plasma BKPyV loads >3 log10 c/mL (probable PyVAN), (Moderate, Strong)
317067
- or to be increasing to plasma BKPyV loads of >4 log10 c/mL (presumptive PyVAN).
317067
In kidney transplant patients without increased risk of acute rejection and baseline renal function, renal allograft biopsy is not required prior to reducing immunosuppression. (Moderate, Strong)
317067
A minimum of two biopsy cores should be taken, preferentially containing also medullary tissues. (Moderate, Strong)
317067
The diagnosis of proven PyVAN should be sought by demonstrat ing cytopathic changes of tubular epithelial cells in the allograft tissue, and confirmed by immunohistochemistry or in situ hybrid ization (“proven PyVAN”). (High, Strong)
317067
The histological findings of proven PyVAN should be semi‐quantitatively assessed using the AST‐IDCOP 2013 as well as the Banff 2017 Study group proposal. (High, Strong)
317067
In kidney transplant patients with proven PyVAN and the absence of BKPyV-DNAemia in blood, urine, and graft tissue, JCPyV-associated nephropathy should be considered and specific QNAT be sought on urine, blood, and allograft tissue. (Moderate, Strong)
317067
For the diagnosis of acute rejection and concurrent PyVAN, the presence of endarteritis, fibrinoid vascular necrosis, glomerulitis, or C4d deposits along peritubular capillaries should be documented. (Low, Strong)
317067
In kidney transplant patients with sustained BKPyV‐DNAemia and biopsy‐proven acute rejection as evidenced by intimal arteritis or positive C4d stain (with or without proven PyVAN), antirejection therapy should be given first followed by reducing immunosuppression in a second step. (Low, Strong)
317067
The primary treatment of sustained BKPyV-DNAemia/probable PyVAN, presumptive PyVAN, or proven PyVAN in kidney trans plant patients without concurrent acute rejection is reducing maintenance immunosuppression. (Moderate, Strong)
317067
Tacrolimus trough levels are commonly targeted to <6 ng/mL, (Moderate, Strong)
317067
- cyclosporine trough levels to <150 ng/mL,
317067
- mycophenolate mofetil/mycophenolic acid daily dose equivalents of less or equal than half of the daily maintenance dose,
317067
and sirolimus trough levels of <6 ng/mL. (Very Low, Weak)
317067
Additional strategies have been switching from tacrolimus to low-dose cyclosporine‐A, or switching from the calcineurin inhibitors to sirolimus, or switching from mycophenolic acid to low‐dose sirolimus, or from mycophenolic acid to leflunomide. (Very Low, Weak)
317067
In patients with sustained BKPyV-DNAemia/probable PyVAN, presumptive PyVAN, or proven PyVAN, despite adequately reduced immunosuppression, the use of adjunctive therapies may be considered. (Low, Weak)
317067
Return to routine maintenance immunosuppression after suc cessful clearance of BKPyV-DNAemia should be considered under careful monitoring plasma viral loads to counteract rejection. (Very Low, Weak)
317067
Acute rejection after reducing immunosuppression for BKPyV-DNAemia, presumptive, or proven PyVAN should be treated according to standard protocols. (Low, Weak)
317067
Retransplantation can be considered for patients after loss of a first kidney allograft due to PyVAN, but frequent screening for BKPyV replication is recommended. (Low, Strong)
317067
Recommendation Grading
Overview
Title
BK Polyomavirus In Solid Organ Transplantation
Authoring Organization
American Society of Transplantation
Publication Month/Year
April 1, 2019
Last Updated Month/Year
July 7, 2022
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
The present AST‐IDCOP guidelines update information on BK polyomavirus (BKPyV) infection, replication, and disease, which impact kidney transplantation (KT), but rarely non‐kidney solid organ transplantation (SOT)
Target Patient Population
Kidney transplantation patients
Inclusion Criteria
Female, Male, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Operating and recovery room, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Prevention, Management, Treatment
Diseases/Conditions (MeSH)
D014180 - Transplantation, D016030 - Kidney Transplantation, D016377 - Organ Transplantation, D011120 - Polyomavirus, D027601 - Polyomavirus Infections, D001739 - BK Virus
Keywords
antiviral, prophylaxis, renal transplant, antimicrobial prophylaxis, nephropathy, solid organ transplant, polyoma, BK virus
Source Citation
Hirsch, HH, Randhawa, PS; on behalf of AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33:e13528.